Isentress (raltegravir) is a new HIV drug in Canada

January 2008

Isentress (raltegravir) is a new HIV drug in Canada.

It's the first in a new class called integrase inhibitors.

HIV integrase is one of three enzymes needed by HIV to reproduce. Older drugs block either of the other two enzymes...reverse transcriptase or protease.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

whether they can drink alcohol with their medications
Cardiology new antihypertensive called Rasilez, the first direct renin inhibitor
Cardiology whether a beta-blocker should be started before noncardiac surgery
Antidepressants new antidepressant called Cymbalta
Psychiatry new antipsychotics on the Canadian market
Women's Health More women will get shorter courses of nitrofurantoin for uncomplicated bladder infections
Respiratory & Allergy Many patients are getting both Spiriva and ipratropium together
Infectious Diseases Isentress (raltegravir) is a new HIV drug in Canada
Gastroenterology Mezavant will be the first ONCE-daily oral mesalamine
Diabetes & Endocrinology Nasal desmopressin (DDAVP, etc) shouldn't be used for bedwetting anymore
Alzheimer's Disease Exelon (rivastigmine) now comes in a once-daily PATCH
Ophthalmology A new controversy about eyelash enhancers
Vaccines meningococcal C booster dose is now recommended for babies who finish the series before 12 months old
Pediatrics alternatives to traditional OTC cough and cold medicines for infants and young children

Isentress (raltegravir) is a new HIV drug in Canada

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents